Side effects of interferon on endocrine and respiratory system in 545 cases of chronic hepatitis C
We investigated the side effects of interferon (IFN) on the endocrine and respiratory system in 545 cases of chronic hepatitis C. Eleven of 494 (2.2%) patients with chronic hepatitis C who were treated with natural or recombinant interferon (IFN) developed thyroid disease while on treatment. Eight p...
Gespeichert in:
| Veröffentlicht in: | Nippon Shokakibyo Gakkai Zasshi 1994, Vol.91(5), pp.995-1002 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | jpn |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1002 |
|---|---|
| container_issue | 5 |
| container_start_page | 995 |
| container_title | Nippon Shokakibyo Gakkai Zasshi |
| container_volume | 91 |
| creator | OKANOUE, Takeshi SAKAMOTO, Shinichi YASUI, Koichiro TAKAMI, Shiro ENJO, Fumio KASHIMA, Kei NAKAGAWA, Yoshihiro TADA, Hisashi KANAOKA, Hikoharu OHTA, Masaharu FUKUI, Susumu KAGAWA, Keizo SAWA, Yoshihiko OHKAWARA, Yasuo KATSUMA, Yoshinori ITO, Yoshito TSUJI, Shunzo |
| description | We investigated the side effects of interferon (IFN) on the endocrine and respiratory system in 545 cases of chronic hepatitis C. Eleven of 494 (2.2%) patients with chronic hepatitis C who were treated with natural or recombinant interferon (IFN) developed thyroid disease while on treatment. Eight patients developed hyperthyroidism and 3 patients developed hypothyroidism. All 11 patients required definitive therapy, who became euthyroid after the therapy. Two patients received nIFNα and one patient received rIFNα2b developed diabetes mellitus. Two patients received rIFNα2a and rIFNα2b, respectively, developed interstitial pneumonia 12 weeks and 24 weeks later, respectively. One patient showed positive reaction for RA test and LE factor and positive LE cell, and complained of fever, arthralgia and dry cough. These phenomenon disappeared after the cessation of IFN therapy. |
| doi_str_mv | 10.11405/nisshoshi1964.91.995 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_76511337</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>76511337</sourcerecordid><originalsourceid>FETCH-LOGICAL-j1194-f1036451b1f6477dcbe95aabf6e1e11320101a0f8f2ebd39e42fe2a7f47de8f93</originalsourceid><addsrcrecordid>eNpVkEtrwzAQhEVpSUOanxDQqTenWuvh6FhCXxDooe3ZyPKqVvCrknLIv69pQqCwzB7mmzkMIStgawDB5EPvY2yG2HjQSqw1rLWWV2QOXOisUJpfkzkTQmVKbtQtWcboK8aYlnrD-YzMCgkScjEn1YevkaJzaFOkg6O-TxgchqGn02FfDzb4Hqnpaxowjj6YNIQjjceYsJtwKoWk1kT8i9tmSnpLGxxN8slHur0jN860EZfnvyBfz0-f29ds9_7ytn3cZXsALTIHjCshoQKnRFHUtkItjamcQkAAnjNgYJjbuByrmmsUucPcFE4UNW6c5gtyf-odw_BzwJjKzkeLbWt6HA6xLJScangxgaszeKg6rMsx-M6EY3keZfLfTv4-JvONF9-E5G2L5b_tSw2lPIuWF8Y2JpTY81_vZ4Jo</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>76511337</pqid></control><display><type>article</type><title>Side effects of interferon on endocrine and respiratory system in 545 cases of chronic hepatitis C</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>OKANOUE, Takeshi ; SAKAMOTO, Shinichi ; YASUI, Koichiro ; TAKAMI, Shiro ; ENJO, Fumio ; KASHIMA, Kei ; NAKAGAWA, Yoshihiro ; TADA, Hisashi ; KANAOKA, Hikoharu ; OHTA, Masaharu ; FUKUI, Susumu ; KAGAWA, Keizo ; SAWA, Yoshihiko ; OHKAWARA, Yasuo ; KATSUMA, Yoshinori ; ITO, Yoshito ; TSUJI, Shunzo</creator><creatorcontrib>OKANOUE, Takeshi ; SAKAMOTO, Shinichi ; YASUI, Koichiro ; TAKAMI, Shiro ; ENJO, Fumio ; KASHIMA, Kei ; NAKAGAWA, Yoshihiro ; TADA, Hisashi ; KANAOKA, Hikoharu ; OHTA, Masaharu ; FUKUI, Susumu ; KAGAWA, Keizo ; SAWA, Yoshihiko ; OHKAWARA, Yasuo ; KATSUMA, Yoshinori ; ITO, Yoshito ; TSUJI, Shunzo</creatorcontrib><description>We investigated the side effects of interferon (IFN) on the endocrine and respiratory system in 545 cases of chronic hepatitis C. Eleven of 494 (2.2%) patients with chronic hepatitis C who were treated with natural or recombinant interferon (IFN) developed thyroid disease while on treatment. Eight patients developed hyperthyroidism and 3 patients developed hypothyroidism. All 11 patients required definitive therapy, who became euthyroid after the therapy. Two patients received nIFNα and one patient received rIFNα2b developed diabetes mellitus. Two patients received rIFNα2a and rIFNα2b, respectively, developed interstitial pneumonia 12 weeks and 24 weeks later, respectively. One patient showed positive reaction for RA test and LE factor and positive LE cell, and complained of fever, arthralgia and dry cough. These phenomenon disappeared after the cessation of IFN therapy.</description><identifier>ISSN: 0446-6586</identifier><identifier>EISSN: 1349-7693</identifier><identifier>DOI: 10.11405/nisshoshi1964.91.995</identifier><identifier>PMID: 7515124</identifier><language>jpn</language><publisher>Japan: The Japanese Society of Gastroenterology</publisher><subject>Adult ; Chronic Disease ; Diabetes Mellitus - etiology ; Female ; Hepatitis C - therapy ; Humans ; Hyperthyroidism - etiology ; Hypothyroidism - etiology ; Interferon-alpha - adverse effects ; Interferon-beta - adverse effects ; Interferons - adverse effects ; Lung Diseases, Interstitial - etiology ; Male ; Middle Aged ; Recombinant Proteins ; SLE</subject><ispartof>Nippon Shokakibyo Gakkai Zasshi, 1994, Vol.91(5), pp.995-1002</ispartof><rights>The Japanese Society of Gastroenterology</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/7515124$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>OKANOUE, Takeshi</creatorcontrib><creatorcontrib>SAKAMOTO, Shinichi</creatorcontrib><creatorcontrib>YASUI, Koichiro</creatorcontrib><creatorcontrib>TAKAMI, Shiro</creatorcontrib><creatorcontrib>ENJO, Fumio</creatorcontrib><creatorcontrib>KASHIMA, Kei</creatorcontrib><creatorcontrib>NAKAGAWA, Yoshihiro</creatorcontrib><creatorcontrib>TADA, Hisashi</creatorcontrib><creatorcontrib>KANAOKA, Hikoharu</creatorcontrib><creatorcontrib>OHTA, Masaharu</creatorcontrib><creatorcontrib>FUKUI, Susumu</creatorcontrib><creatorcontrib>KAGAWA, Keizo</creatorcontrib><creatorcontrib>SAWA, Yoshihiko</creatorcontrib><creatorcontrib>OHKAWARA, Yasuo</creatorcontrib><creatorcontrib>KATSUMA, Yoshinori</creatorcontrib><creatorcontrib>ITO, Yoshito</creatorcontrib><creatorcontrib>TSUJI, Shunzo</creatorcontrib><title>Side effects of interferon on endocrine and respiratory system in 545 cases of chronic hepatitis C</title><title>Nippon Shokakibyo Gakkai Zasshi</title><addtitle>Nippon Shokakibyo Gakkai Zasshi</addtitle><description>We investigated the side effects of interferon (IFN) on the endocrine and respiratory system in 545 cases of chronic hepatitis C. Eleven of 494 (2.2%) patients with chronic hepatitis C who were treated with natural or recombinant interferon (IFN) developed thyroid disease while on treatment. Eight patients developed hyperthyroidism and 3 patients developed hypothyroidism. All 11 patients required definitive therapy, who became euthyroid after the therapy. Two patients received nIFNα and one patient received rIFNα2b developed diabetes mellitus. Two patients received rIFNα2a and rIFNα2b, respectively, developed interstitial pneumonia 12 weeks and 24 weeks later, respectively. One patient showed positive reaction for RA test and LE factor and positive LE cell, and complained of fever, arthralgia and dry cough. These phenomenon disappeared after the cessation of IFN therapy.</description><subject>Adult</subject><subject>Chronic Disease</subject><subject>Diabetes Mellitus - etiology</subject><subject>Female</subject><subject>Hepatitis C - therapy</subject><subject>Humans</subject><subject>Hyperthyroidism - etiology</subject><subject>Hypothyroidism - etiology</subject><subject>Interferon-alpha - adverse effects</subject><subject>Interferon-beta - adverse effects</subject><subject>Interferons - adverse effects</subject><subject>Lung Diseases, Interstitial - etiology</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Recombinant Proteins</subject><subject>SLE</subject><issn>0446-6586</issn><issn>1349-7693</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1994</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkEtrwzAQhEVpSUOanxDQqTenWuvh6FhCXxDooe3ZyPKqVvCrknLIv69pQqCwzB7mmzkMIStgawDB5EPvY2yG2HjQSqw1rLWWV2QOXOisUJpfkzkTQmVKbtQtWcboK8aYlnrD-YzMCgkScjEn1YevkaJzaFOkg6O-TxgchqGn02FfDzb4Hqnpaxowjj6YNIQjjceYsJtwKoWk1kT8i9tmSnpLGxxN8slHur0jN860EZfnvyBfz0-f29ds9_7ytn3cZXsALTIHjCshoQKnRFHUtkItjamcQkAAnjNgYJjbuByrmmsUucPcFE4UNW6c5gtyf-odw_BzwJjKzkeLbWt6HA6xLJScangxgaszeKg6rMsx-M6EY3keZfLfTv4-JvONF9-E5G2L5b_tSw2lPIuWF8Y2JpTY81_vZ4Jo</recordid><startdate>199405</startdate><enddate>199405</enddate><creator>OKANOUE, Takeshi</creator><creator>SAKAMOTO, Shinichi</creator><creator>YASUI, Koichiro</creator><creator>TAKAMI, Shiro</creator><creator>ENJO, Fumio</creator><creator>KASHIMA, Kei</creator><creator>NAKAGAWA, Yoshihiro</creator><creator>TADA, Hisashi</creator><creator>KANAOKA, Hikoharu</creator><creator>OHTA, Masaharu</creator><creator>FUKUI, Susumu</creator><creator>KAGAWA, Keizo</creator><creator>SAWA, Yoshihiko</creator><creator>OHKAWARA, Yasuo</creator><creator>KATSUMA, Yoshinori</creator><creator>ITO, Yoshito</creator><creator>TSUJI, Shunzo</creator><general>The Japanese Society of Gastroenterology</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>199405</creationdate><title>Side effects of interferon on endocrine and respiratory system in 545 cases of chronic hepatitis C</title><author>OKANOUE, Takeshi ; SAKAMOTO, Shinichi ; YASUI, Koichiro ; TAKAMI, Shiro ; ENJO, Fumio ; KASHIMA, Kei ; NAKAGAWA, Yoshihiro ; TADA, Hisashi ; KANAOKA, Hikoharu ; OHTA, Masaharu ; FUKUI, Susumu ; KAGAWA, Keizo ; SAWA, Yoshihiko ; OHKAWARA, Yasuo ; KATSUMA, Yoshinori ; ITO, Yoshito ; TSUJI, Shunzo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-j1194-f1036451b1f6477dcbe95aabf6e1e11320101a0f8f2ebd39e42fe2a7f47de8f93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>jpn</language><creationdate>1994</creationdate><topic>Adult</topic><topic>Chronic Disease</topic><topic>Diabetes Mellitus - etiology</topic><topic>Female</topic><topic>Hepatitis C - therapy</topic><topic>Humans</topic><topic>Hyperthyroidism - etiology</topic><topic>Hypothyroidism - etiology</topic><topic>Interferon-alpha - adverse effects</topic><topic>Interferon-beta - adverse effects</topic><topic>Interferons - adverse effects</topic><topic>Lung Diseases, Interstitial - etiology</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Recombinant Proteins</topic><topic>SLE</topic><toplevel>online_resources</toplevel><creatorcontrib>OKANOUE, Takeshi</creatorcontrib><creatorcontrib>SAKAMOTO, Shinichi</creatorcontrib><creatorcontrib>YASUI, Koichiro</creatorcontrib><creatorcontrib>TAKAMI, Shiro</creatorcontrib><creatorcontrib>ENJO, Fumio</creatorcontrib><creatorcontrib>KASHIMA, Kei</creatorcontrib><creatorcontrib>NAKAGAWA, Yoshihiro</creatorcontrib><creatorcontrib>TADA, Hisashi</creatorcontrib><creatorcontrib>KANAOKA, Hikoharu</creatorcontrib><creatorcontrib>OHTA, Masaharu</creatorcontrib><creatorcontrib>FUKUI, Susumu</creatorcontrib><creatorcontrib>KAGAWA, Keizo</creatorcontrib><creatorcontrib>SAWA, Yoshihiko</creatorcontrib><creatorcontrib>OHKAWARA, Yasuo</creatorcontrib><creatorcontrib>KATSUMA, Yoshinori</creatorcontrib><creatorcontrib>ITO, Yoshito</creatorcontrib><creatorcontrib>TSUJI, Shunzo</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Nippon Shokakibyo Gakkai Zasshi</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>OKANOUE, Takeshi</au><au>SAKAMOTO, Shinichi</au><au>YASUI, Koichiro</au><au>TAKAMI, Shiro</au><au>ENJO, Fumio</au><au>KASHIMA, Kei</au><au>NAKAGAWA, Yoshihiro</au><au>TADA, Hisashi</au><au>KANAOKA, Hikoharu</au><au>OHTA, Masaharu</au><au>FUKUI, Susumu</au><au>KAGAWA, Keizo</au><au>SAWA, Yoshihiko</au><au>OHKAWARA, Yasuo</au><au>KATSUMA, Yoshinori</au><au>ITO, Yoshito</au><au>TSUJI, Shunzo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Side effects of interferon on endocrine and respiratory system in 545 cases of chronic hepatitis C</atitle><jtitle>Nippon Shokakibyo Gakkai Zasshi</jtitle><addtitle>Nippon Shokakibyo Gakkai Zasshi</addtitle><date>1994-05</date><risdate>1994</risdate><volume>91</volume><issue>5</issue><spage>995</spage><epage>1002</epage><pages>995-1002</pages><issn>0446-6586</issn><eissn>1349-7693</eissn><abstract>We investigated the side effects of interferon (IFN) on the endocrine and respiratory system in 545 cases of chronic hepatitis C. Eleven of 494 (2.2%) patients with chronic hepatitis C who were treated with natural or recombinant interferon (IFN) developed thyroid disease while on treatment. Eight patients developed hyperthyroidism and 3 patients developed hypothyroidism. All 11 patients required definitive therapy, who became euthyroid after the therapy. Two patients received nIFNα and one patient received rIFNα2b developed diabetes mellitus. Two patients received rIFNα2a and rIFNα2b, respectively, developed interstitial pneumonia 12 weeks and 24 weeks later, respectively. One patient showed positive reaction for RA test and LE factor and positive LE cell, and complained of fever, arthralgia and dry cough. These phenomenon disappeared after the cessation of IFN therapy.</abstract><cop>Japan</cop><pub>The Japanese Society of Gastroenterology</pub><pmid>7515124</pmid><doi>10.11405/nisshoshi1964.91.995</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0446-6586 |
| ispartof | Nippon Shokakibyo Gakkai Zasshi, 1994, Vol.91(5), pp.995-1002 |
| issn | 0446-6586 1349-7693 |
| language | jpn |
| recordid | cdi_proquest_miscellaneous_76511337 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Adult Chronic Disease Diabetes Mellitus - etiology Female Hepatitis C - therapy Humans Hyperthyroidism - etiology Hypothyroidism - etiology Interferon-alpha - adverse effects Interferon-beta - adverse effects Interferons - adverse effects Lung Diseases, Interstitial - etiology Male Middle Aged Recombinant Proteins SLE |
| title | Side effects of interferon on endocrine and respiratory system in 545 cases of chronic hepatitis C |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-14T11%3A56%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Side%20effects%20of%20interferon%20on%20endocrine%20and%20respiratory%20system%20in%20545%20cases%20of%20chronic%20hepatitis%20C&rft.jtitle=Nippon%20Shokakibyo%20Gakkai%20Zasshi&rft.au=OKANOUE,%20Takeshi&rft.date=1994-05&rft.volume=91&rft.issue=5&rft.spage=995&rft.epage=1002&rft.pages=995-1002&rft.issn=0446-6586&rft.eissn=1349-7693&rft_id=info:doi/10.11405/nisshoshi1964.91.995&rft_dat=%3Cproquest_pubme%3E76511337%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=76511337&rft_id=info:pmid/7515124&rfr_iscdi=true |